VOLPINI, Rosaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.830
EU - Europa 8.920
AS - Asia 6.857
SA - Sud America 955
AF - Africa 257
Continente sconosciuto - Info sul continente non disponibili 50
OC - Oceania 13
Totale 35.882
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.233
CN - Cina 2.777
SG - Singapore 2.086
RU - Federazione Russa 1.958
PL - Polonia 1.552
IT - Italia 1.393
DE - Germania 974
BR - Brasile 799
GB - Regno Unito 623
HK - Hong Kong 544
UA - Ucraina 538
SE - Svezia 524
FR - Francia 523
CA - Canada 514
VN - Vietnam 479
FI - Finlandia 365
KR - Corea 229
TR - Turchia 219
ZA - Sudafrica 181
IE - Irlanda 137
IN - India 119
JP - Giappone 100
MX - Messico 61
NL - Olanda 60
AR - Argentina 55
BE - Belgio 49
EU - Europa 49
ES - Italia 46
BD - Bangladesh 42
CZ - Repubblica Ceca 37
IQ - Iraq 35
IR - Iran 33
AT - Austria 28
EC - Ecuador 24
PK - Pakistan 20
VE - Venezuela 20
RO - Romania 18
UZ - Uzbekistan 18
CO - Colombia 17
ID - Indonesia 17
TW - Taiwan 17
AE - Emirati Arabi Uniti 16
LT - Lituania 15
SA - Arabia Saudita 15
KE - Kenya 14
CH - Svizzera 12
CL - Cile 12
IL - Israele 12
JO - Giordania 12
PY - Paraguay 12
TN - Tunisia 12
MA - Marocco 11
RS - Serbia 11
AZ - Azerbaigian 9
DZ - Algeria 9
PE - Perù 9
AU - Australia 8
EG - Egitto 8
NP - Nepal 8
PH - Filippine 8
DK - Danimarca 7
LB - Libano 7
BG - Bulgaria 6
AM - Armenia 5
CI - Costa d'Avorio 5
GR - Grecia 5
LV - Lettonia 5
PA - Panama 5
BO - Bolivia 4
GE - Georgia 4
HR - Croazia 4
JM - Giamaica 4
KZ - Kazakistan 4
MY - Malesia 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
TH - Thailandia 4
AL - Albania 3
BY - Bielorussia 3
CR - Costa Rica 3
EE - Estonia 3
ET - Etiopia 3
KH - Cambogia 3
LU - Lussemburgo 3
NO - Norvegia 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
CM - Camerun 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GT - Guatemala 2
HU - Ungheria 2
KW - Kuwait 2
MT - Malta 2
MU - Mauritius 2
OM - Oman 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
Totale 35.862
Salva come PNG Salva come JPEG
Città #
Fairfield 1.762
Ashburn 1.548
Woodbridge 1.493
Warsaw 1.349
Jacksonville 1.322
Houston 1.066
Singapore 1.063
Chandler 1.053
San Jose 827
Seattle 783
Wilmington 753
Ann Arbor 647
Cambridge 605
Boardman 564
Dallas 562
Hong Kong 517
Nanjing 463
Beijing 430
Toronto 331
The Dalles 278
Los Angeles 253
Camerino 245
Seoul 204
San Mateo 199
Columbus 189
Tongling 189
Dearborn 188
New York 187
Kraków 185
Lawrence 180
Princeton 180
Düsseldorf 175
Helsinki 173
Istanbul 168
Lauterbourg 162
Johannesburg 160
Ogden 146
Ho Chi Minh City 142
Dublin 136
London 130
Buffalo 128
Lachine 128
Moscow 124
Nanchang 123
Council Bluffs 113
Hanoi 110
Shanghai 102
Chicago 99
Guangzhou 97
Shenyang 91
São Paulo 90
Milan 88
Munich 88
Santa Clara 87
Tianjin 85
San Diego 84
Tokyo 81
Frankfurt am Main 78
Kunming 74
Hebei 62
Jiaxing 56
Orem 53
Brussels 48
Edinburgh 46
Changsha 40
Jinan 39
Redwood City 39
Wuhan 39
Denver 38
Ningbo 38
Phoenix 38
Centro 37
Rome 37
Hangzhou 36
Atlanta 35
Dong Ket 35
Stockholm 35
Manchester 34
Trieste 33
Boston 31
Turku 31
Venezia 31
Philadelphia 30
Zhengzhou 30
Brooklyn 29
Poplar 29
San Francisco 29
Verona 29
Chennai 28
Hefei 27
Rio de Janeiro 27
Brno 25
Falls Church 25
Montreal 25
Norwalk 25
Amsterdam 24
Orange 24
Redondo Beach 23
Detroit 22
Jinhua 22
Totale 24.261
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 635
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 437
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 402
Overview on Radiolabel-Free in Vitro Assays for GPCRs 397
Pharmacological characterization of the GPR17 receptor dual profile 379
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 376
GPR17 receptor modulators and their therapeutic implications: review of recent patents 373
The G Protein-Coupled Receptor GPR17: Overview and Update 366
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 358
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 348
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 304
Medicinal chemistry and pharmacology of A2B adenosine receptors 295
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 290
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 288
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 286
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 280
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease 272
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 271
2-Aralkynyl and 2-Heteroalkynyl derivatives of Adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists 266
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 265
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 263
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 263
2-Substituted N-ethylcarboxamidoadenosine derivatives as high affinity agonists at human A(3) adenosine receptors 256
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 255
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors 250
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 247
Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1 246
9-ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities 245
3'-Deoxyribofuranose derivatives of 1-deaza and 3-deaza adenosine and their activity as adenosine deaminase inhibitors 244
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 244
A(2A) adenosine receptor agonists reduce both high-palatability and low-palatability food intake in female rats 240
2-Alkynyl derivatives of Adenosine-5'-N-ethyluronamide (NECA): selective A2 adenosine receptor agonists with potent inhibitory activity on Platelet aggregation 238
Human placenta cytidine deaminase: a zinc metalloprotein 237
Biomarkers mapping of neuropathic pain in a nerve chronic constriction injury mice model 236
Human cytidine deaminase: understanding the catalytic mechanism 235
Determination of ink photoinitiators in packaged beverages by gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry 235
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 234
Isoenzymatic forms of human cytidine deaminase 233
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 233
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 231
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 230
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 230
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 227
Purine and deazapurine nucleosides: synthetic approaches, molecular modeling and biological activity 226
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 226
Adenosine deaminase: Functional implications and different classes of inhibitors 223
Adenosine deaminase inhibitors: synthesis and structure-activity relationships of 2-hydroxy-3-nonyl derivatives of azoles 223
New sensible method to quantize the intestinal absorption of receptor ligands 222
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 221
2- And 8- alkynyladenosines: conformational studies and docking to human adenosine A(3) receptor can explain their different biological behavior 220
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 219
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 218
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 216
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 216
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 214
Antiviral properties of deazaadenine nucleoside derivatives 214
Antiviral activity of purine nucleoside analogs against bovine herpesvirus (BHV-1) and maedi visna virus (MVV) 213
CX3CL1-induced modulation at CA1 synapses reveals multiple mechanisms of EPSC modulation involving adenosine receptor subtypes. 211
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 210
2-Alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors 210
"N-Cycloalkylalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists at the A1 adenosine receptor 208
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 207
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 204
Diazepinone nucleosides as inhibitors of cytidine deaminase 203
Adenosine receptor modeling: what does the A2A crystal structure tell us? 203
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family 203
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 203
2- And 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosines receptors 203
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 201
2-phenylhydroxypropynyladenosine derivatives as high potent agonists at A(2B) adenosine receptor subtype 200
2-substituted 5 '-N-methylcarboxamidoadenosine (MECA) derivatives as A(3) adenosine receptor ligands 199
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 199
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 198
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 198
Ring opening reactions: synthesis of AICAR analogs as potential antimetabolite agents 197
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 197
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 196
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 196
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 195
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 193
Synthesis and receptor affinity of polysubstituted adenosines 191
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 191
Unexpected synthesis of acyclic adenine nucleosides 190
Chemical and pharmacological profile of selective adenosine receptor agonists 190
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 189
2-ChloroATP exerts anti-tumoral actions not mediated by P2 receptors in neuronal and glial cells line 189
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 189
Adenosine deaminase inhibitors: structure-activity relationships in 1-deazaadenosine and erythro-9-(2-hydroxy-3-nonyl)adenine analogs 185
Potent and selective ligands for adenosine binding sites 185
[3H]HEMADO – a novel tritiated agonist selective for the human adenosine A(3) receptor 185
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 185
Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor 184
Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity 184
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 184
A(2B) adenosine receptor agonists: synthesis and biological evaluation of 2-phenylhydroxypropynyladenosine and NECA derivatives 182
Adenosine deaminase inhibitors: synthesis, diastereoisomeric resolution and biological activity of 1-(2-hydroxy-3-nonyl)-1,2,4-triazole-3-carboxamide 181
9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution result in distinct selectivities. 181
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 181
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 180
Synthesis and adenosine deaminase inhibitory activity of 3’-deoxy-1-deazaadenosines 180
Totale 23.851
Salva come PNG Salva come JPEG
Categoria #
all - tutte 137.924
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.924
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.200 0 0 0 0 0 0 0 0 0 210 602 388
2021/20222.229 234 534 55 91 122 119 102 167 170 235 157 243
2022/20232.525 256 144 76 420 277 361 11 154 461 134 165 66
2023/20241.883 265 100 110 76 87 173 87 104 222 62 49 548
2024/20256.213 231 140 527 295 200 361 709 1.540 518 436 382 874
2025/20268.067 538 524 1.072 1.240 984 701 1.487 581 511 429 0 0
Totale 36.355